Page 1 of Clinical Trials for PharmaBio Development Inc. [SPONSOR-COLLABORATORS], 11 Total Matches

Show/Hide Clinical Trials Which are Not Seeking New Volunteers

1
Recruiting
E7050 in Combination With Cisplatin and Capecitabine Versus Cisplatin and Capecitabine Alone in Patients With Advanced or Metastatic Solid Tumors and Previously Untreated Gastric Cancer
Last Updated: April 4, 2012
Condition(s): Advanced or Metastatic Solid Tumors; Previously Untreated Gastric Cancer
2
Recruiting
E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Patients With Hepatocellular Carcinoma
Last Updated: April 4, 2012
Condition(s): Hepatocellular Carcinoma
3
Recruiting
A Study Comparing the Combination of the Best Supportive Care Plus E7080 Versus Best Supportive Care Alone, in Patients With Advanced Lung Cancer or Lung Cancer That Has Spread, Who Have Been Previously Treated, Unsuccessfully, With at Least 2 Different Treatments
Last Updated: May 18, 2012
Condition(s): Non-Small Cell Lung Cancer
4
Active, not recruiting
Eribulin Mesylate Administered in Combination With Pemetrexed Versus Pemetrexed Alone as Second Line Therapy in Patients With Stage IIIB or IV Nonsquamous Non Small Cell Lung Cancer
Last Updated: April 4, 2012
Condition(s): Non Small Cell Lung Cancer
5
Recruiting
Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer
Last Updated: May 18, 2012
Condition(s): Colon Cancer and Rectal Cancer
6
Suspended
Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer
Last Updated: April 4, 2012
Condition(s): Bladder Cancer
7
Recruiting
Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma
Last Updated: May 18, 2012
Condition(s): Stage IIIC Melanoma; Stage IV Melanoma
8
Terminated
E7080 in Combination With Carboplatin + Gemcitabine Versus Carboplatin + Gemcitabine Alone as Second Line Therapy in Patients With Platinum-Sensitive Recurrent Ovarian Cancer by CA125
Last Updated: April 4, 2012
Condition(s): Ovarian Cancer
9
Recruiting
E7050 in Combination With Cetuximab Versus Cetuximab Alone in the Treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck
Last Updated: April 4, 2012
Condition(s): Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck
10
Active, not recruiting
E7080 in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma
Last Updated: April 10, 2012
Condition(s): Stage IV Melanoma
11
Completed
FOLFIRI Alone Versus FOLFIRI Plus Bevacizumab Versus FOLFIRI Plus E7820 as Second-Line Therapy in Patients With Locally Advanced or Metastatic Colorectal Cancer
Last Updated: April 4, 2012
Condition(s): Colorectal Cancer

Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.

The URL of this page is: http://clinicaltrialsfeeds.org/clinical-trials/results/?spons=PharmaBio+Development+Inc.

Page 1 of Clinical Trials for PharmaBio Development Inc. [SPONSOR-COLLABORATORS], 11 Total Matches

Get the Latest Results via Email or RSS

Subscribe via Web Newsreaders

Browse

Clinical Trials Background

About